$EPIX
ESSA Pharma Inc

2022 Q4 Form 10-K Financial Statement

#000155837022018570 Filed on December 13, 2022

View on sec.gov

Income Statement

Concept 2022 Q4 2022 Q3 2022
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue $0.00 $0.00 $82.49K
YoY Change 23.56%
Gross Profit $0.00 $0.00 -$82.49K
YoY Change 23.56%
Gross Profit Margin
Selling, General & Admin $2.585M $2.772M $12.56M
YoY Change -15.68% -5.91% -2.61%
% of Gross Profit
Research & Development $5.344M $4.351M $24.42M
YoY Change -11.22% -30.63% 0.64%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $7.866M $7.124M $36.97M
YoY Change -13.43% -22.73% -0.52%
Operating Profit -$7.866M -$7.124M -$37.06M
YoY Change -0.47%
Interest Expense $1.124M $733.8K $1.759M
YoY Change -9457.54% 11.17% 461.29%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$6.742M -$6.390M -$35.22M
YoY Change -25.9% -25.34% -4.41%
Income Tax $0.00 -$66.15K -$111.8K
% Of Pretax Income
Net Earnings -$6.742M -$6.324M -$35.10M
YoY Change -25.9% -26.12% -4.62%
Net Earnings / Revenue
Basic Earnings Per Share -$0.15 -$0.80
Diluted Earnings Per Share -$0.15 -$143.5K -$0.80
COMMON SHARES
Basic Shares Outstanding 44.07M 44.07M 44.04M
Diluted Shares Outstanding 44.07M 44.04M

Balance Sheet

Concept 2022 Q4 2022 Q3 2022
SHORT-TERM ASSETS
Cash & Short-Term Investments $163.1M $167.2M $167.2M
YoY Change -13.81% -14.21% -14.21%
Cash & Equivalents $51.22M $57.08M $57.08M
Short-Term Investments $111.9M $110.2M $110.2M
Other Short-Term Assets $1.502M $1.816M $1.816M
YoY Change -14.07% -16.79% -16.79%
Inventory
Prepaid Expenses $1.502M $1.816M
Receivables $14.64K $6.210K $6.210K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $164.6M $169.1M $169.1M
YoY Change -13.81% -14.44% -14.44%
LONG-TERM ASSETS
Property, Plant & Equipment $156.1K $186.5K $186.5K
YoY Change -43.83% -39.51% -39.51%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $259.5K $259.5K $259.5K
YoY Change 0.0% 0.0% 0.0%
Total Long-Term Assets $415.5K $446.0K $446.0K
YoY Change -22.67% -21.45% -21.45%
TOTAL ASSETS
Total Short-Term Assets $164.6M $169.1M $169.1M
Total Long-Term Assets $415.5K $446.0K $446.0K
Total Assets $165.0M $169.5M $169.5M
YoY Change -13.83% -14.46% -14.46%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.635M $954.6K $954.6K
YoY Change 4.67% -33.05% -33.05%
Accrued Expenses $738.4K $807.5K $1.356M
YoY Change -54.85% -60.85% -45.85%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $2.935M $2.310M $2.310M
YoY Change -19.76% -41.21% -41.21%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $48.27K $76.42K $76.42K
YoY Change -83.3% -66.86% -66.86%
Total Long-Term Liabilities $48.27K $76.42K $76.42K
YoY Change -83.3% -66.86% -66.86%
TOTAL LIABILITIES
Total Short-Term Liabilities $2.935M $2.310M $2.310M
Total Long-Term Liabilities $48.27K $76.42K $76.42K
Total Liabilities $2.983M $2.387M $2.387M
YoY Change -24.41% -42.63% -42.63%
SHAREHOLDERS EQUITY
Retained Earnings -$159.6M -$152.9M
YoY Change 25.81% 29.81%
Common Stock $278.1M $278.1M
YoY Change 0.18% 0.24%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $162.0M $167.1M $167.1M
YoY Change
Total Liabilities & Shareholders Equity $165.0M $169.5M $169.5M
YoY Change -13.83% -14.46% -14.46%

Cashflow Statement

Concept 2022 Q4 2022 Q3 2022
OPERATING ACTIVITIES
Net Income -$6.742M -$6.324M -$35.10M
YoY Change -25.9% -26.12% -4.62%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$4.995M -$7.856M -$28.70M
YoY Change -14.17% 6.4% 12.94%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities -$876.3K -$2.969M -$52.35M
YoY Change -92.03% 49.5%
Cash From Investing Activities -$876.3K -$2.969M -$52.35M
YoY Change -92.03% 49.5%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $0.00
YoY Change -100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 15.65K -34.63K 252.7K
YoY Change -84.24% -359.98% -99.82%
NET CHANGE
Cash From Operating Activities -4.995M -7.856M -28.70M
Cash From Investing Activities -876.3K -2.969M -52.35M
Cash From Financing Activities 15.65K -34.63K 252.7K
Net Change In Cash -5.856M -10.86M -80.75M
YoY Change -65.07% 47.35% -199.07%
FREE CASH FLOW
Cash From Operating Activities -$4.995M -$7.856M -$28.70M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022 dei Entity Address State Or Province
EntityAddressStateOrProvince
BC
CY2022 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
V5Z 1K5
CY2022 dei Entity Address Address Line2
EntityAddressAddressLine2
999 West Broadway
CY2022 dei Entity Address City Or Town
EntityAddressCityOrTown
Vancouver
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.80
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.96
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
44038241
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
38480378
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-111821
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-34349
CY2022 dei Entity Central Index Key
EntityCentralIndexKey
0001633932
CY2022 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--09-30
CY2022 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2022 dei Amendment Flag
AmendmentFlag
false
CY2022Q3 us-gaap Debt Securities Available For Sale Accrued Interest After Allowance For Credit Loss Statement Of Financial Position Extensible List
DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2021-01-31#ShortTermInvestments
CY2021Q3 us-gaap Debt Securities Available For Sale Accrued Interest After Allowance For Credit Loss Statement Of Financial Position Extensible List
DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2021-01-31#ShortTermInvestments
CY2021Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
43984346
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
44073076
CY2022 dei Document Type
DocumentType
10-K
CY2022 dei Document Annual Report
DocumentAnnualReport
true
CY2022 dei Document Period End Date
DocumentPeriodEndDate
2022-09-30
CY2022 dei Document Transition Report
DocumentTransitionReport
false
CY2022 dei Entity File Number
EntityFileNumber
001-37410
CY2022 dei Entity Registrant Name
EntityRegistrantName
ESSA Pharma Inc.
CY2022 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
A1
CY2022 dei Entity Address Country
EntityAddressCountry
CA
CY2022 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
47-2569713
CY2022 dei Entity Address Address Line1
EntityAddressAddressLine1
Suite 720
CY2022 dei City Area Code
CityAreaCode
778
CY2022 dei Local Phone Number
LocalPhoneNumber
331-0962
CY2022 dei Security12b Title
Security12bTitle
Common Shares
CY2022 dei Trading Symbol
TradingSymbol
EPIX
CY2022 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2022 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2022 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2022 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2022 dei Entity Small Business
EntitySmallBusiness
true
CY2022 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2022 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2022 dei Entity Shell Company
EntityShellCompany
false
CY2022Q1 dei Entity Public Float
EntityPublicFloat
167700000
CY2022Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
44073076
CY2022 dei Auditor Firm
AuditorFirmId
731
CY2022 dei Auditor Name
AuditorName
DAVIDSON & COMPANY LLP
CY2022 dei Auditor Location
AuditorLocation
Vancouver, Canada
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
57076475
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
137825024
CY2022Q3 us-gaap Short Term Investments
ShortTermInvestments
110161029
CY2021Q3 us-gaap Short Term Investments
ShortTermInvestments
57102159
CY2022Q3 us-gaap Receivables Net Current
ReceivablesNetCurrent
6211
CY2021Q3 us-gaap Receivables Net Current
ReceivablesNetCurrent
489012
CY2022Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1815626
CY2021Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
2181882
CY2022Q3 us-gaap Assets Current
AssetsCurrent
169059341
CY2021Q3 us-gaap Assets Current
AssetsCurrent
197598077
CY2022Q3 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
259455
CY2021Q3 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
259455
CY2022Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
186499
CY2021Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
308286
CY2022Q3 us-gaap Assets
Assets
169505295
CY2021Q3 us-gaap Assets
Assets
198165818
CY2022Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
2176565
CY2021Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
3808944
CY2022Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
133834
CY2021Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
120719
CY2022Q3 us-gaap Liabilities Current
LiabilitiesCurrent
2310399
CY2021Q3 us-gaap Liabilities Current
LiabilitiesCurrent
3929663
CY2022Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
76418
CY2021Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
210251
CY2022Q3 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
0
CY2021Q3 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
20352
CY2022Q3 us-gaap Liabilities
Liabilities
2386817
CY2021Q3 us-gaap Liabilities
Liabilities
4160266
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
44073076
CY2021 us-gaap Accretion Expense
AccretionExpense
9570
CY2022 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
20352
CY2021Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
43984346
CY2022Q3 us-gaap Common Stock Value
CommonStockValue
278089136
CY2021Q3 us-gaap Common Stock Value
CommonStockValue
277415176
CY2022Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
44043503
CY2021Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
36442620
CY2022Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-2135145
CY2021Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-2076479
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-152879016
CY2021Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-117775765
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
167118478
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
194005552
CY2022Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
169505295
CY2021Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
198165818
CY2022 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
24415246
CY2021 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
24258989
CY2022 epix Financing Costs
FinancingCosts
13746
CY2021 epix Financing Costs
FinancingCosts
22220
CY2022 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
12544760
CY2021 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
12884581
CY2022 us-gaap Operating Expenses
OperatingExpenses
36973752
CY2021 us-gaap Operating Expenses
OperatingExpenses
37165790
CY2022 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
1687
CY2021 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-16041
CY2022 us-gaap Interest And Other Income
InterestAndOtherIncome
1736641
CY2021 us-gaap Interest And Other Income
InterestAndOtherIncome
234997
CY2022 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
20352
CY2021 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
107024
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-35215072
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-36839810
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-111821
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-34349
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-35103251
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-36805461
CY2022 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-58666
CY2021 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
0
CY2022 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-35161917
CY2021 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-36805461
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.80
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.96
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
44038241
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
38480378
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-35103251
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-36805461
CY2022 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
121787
CY2021 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
109464
CY2022 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-69653
CY2021 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
0
CY2022 us-gaap Accretion Expense
AccretionExpense
13305
CY2021 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
107024
CY2022 epix Interest Income Operating Activities
InterestIncomeOperatingActivities
894233
CY2021 epix Interest Income Operating Activities
InterestIncomeOperatingActivities
76056
CY2022 us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
-845
CY2021 us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
-31192
CY2022 us-gaap Share Based Compensation
ShareBasedCompensation
7888085
CY2021 us-gaap Share Based Compensation
ShareBasedCompensation
9476113
CY2022 us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
-482801
CY2021 us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
157575
CY2022 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-366256
CY2021 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
563572
CY2022 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-1629065
CY2021 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
2667738
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-28704169
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-25415611
CY2022 us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
296012498
CY2021 us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
57026103
CY2022 us-gaap Proceeds From Sale Of Short Term Investments
ProceedsFromSaleOfShortTermInvestments
242959084
CY2021 us-gaap Proceeds From Sale Of Short Term Investments
ProceedsFromSaleOfShortTermInvestments
22000000
CY2022 epix Interest From Short Term Investments
InterestFromShortTermInvestments
705020
CY2021 epix Interest From Short Term Investments
InterestFromShortTermInvestments
11337
CY2022 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-52348394
CY2021 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-35014766
CY2022 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0
CY2021 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
149999985
CY2022 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
0
CY2021 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
9229450
CY2022 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
319832
CY2021 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1186833
CY2022 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
0
CY2021 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
596
CY2022 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
66926
CY2021 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
133071
CY2022 epix Operating Lease Payments Financing Activities
OperatingLeasePaymentsFinancingActivities
134023
CY2021 epix Operating Lease Payments Financing Activities
OperatingLeasePaymentsFinancingActivities
100282
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
252735
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
141990753
CY2022 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
51279
CY2021 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-56115
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-80748549
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
81504261
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
137825024
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
56320763
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
57076475
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
137825024
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
79243865
CY2021 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
149999985
CY2021 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
9229450
CY2021 epix Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
596
CY2021 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1186833
CY2021 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
133071
CY2021 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
9476113
CY2021 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-36805461
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
194005552
CY2022 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
319832
CY2022 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
66926
CY2022 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7888085
CY2022 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-35161917
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
167118478
CY2022 us-gaap Nature Of Operations
NatureOfOperations
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">1.     NATURE OF OPERATIONS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Nature of Operations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">ESSA Pharma Inc. (the “Company”) was incorporated under the laws of the Province of British Columbia on January 6, 2009. The Company’s head office address is Suite 720 – 999 West Broadway, Vancouver, BC, V5Z 1K5. The registered and records office address is the 26<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">th</sup> Floor at 595 Burrard Street, Three Bentall Centre, Vancouver, BC, V7X 1L3. The Company is listed on the Nasdaq Capital Market (“Nasdaq”) under the symbol “EPIX”. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company is focused on the development of small molecule drugs for the treatment of prostate cancer. The Company has a license to certain patents (the “NTD Technology”) which were the joint property of the British Columbia Cancer Agency and the University of British Columbia. As at September 30, 2022, no products are in commercial production or use.</p>
CY2022Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
210252
CY2022Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
133834
CY2022Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
76418
CY2022Q3 us-gaap Lessee Operating Lease Discount Rate
LesseeOperatingLeaseDiscountRate
0.050
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
3.68
CY2022 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Use of Estimates</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The preparation of the accompanying consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions about future events that affect the reported amounts of assets, liabilities, expenses, contingent assets and contingent liabilities as at the end of, or during, the reporting period. Actual results could significantly differ from those estimates. Significant areas requiring management to make estimates include the derivative liabilities, the valuation of equity instruments issued for services, income taxes and the product development and relocation grant. Further details of the nature of these assumptions and conditions may be found in the relevant notes to these consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The effect of a change in an accounting estimate is recognized prospectively by including it in comprehensive income in the period of the change, if the change affects that period only, or in the period of the change and future periods, if the change affects both. Significant assumptions about the future and other sources of estimation uncertainty that management has made at the statement of financial position date, that could result in a material adjustment to the carrying amounts of assets and liabilities, in the event that actual results differ from assumptions that have been made, relate to the following key estimates:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;font-weight:normal;">Income tax</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The determination of income tax is inherently complex and requires making certain estimates and assumptions about future events. Changes in facts and circumstances as a result of income tax audits, reassessments, changes to corporate structure and associated domiciling, jurisprudence and any new legislation may result in an increase or decrease the provision for income taxes. The value of deferred tax assets is evaluated based on the probability of realization; the Company has assessed that it is improbable that such assets will be realized and has accordingly not recognized a value for deferred taxes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;font-weight:normal;">Share-based payments and compensation</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The Company has applied estimates with respect to the valuation of shares issued for non-cash consideration. Shares are valued at the fair value of the equity instruments granted at the date the Company receives the goods or services.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The Company measures the cost of equity-settled transactions with employees by reference to the fair value of the equity instruments at the date at which they are granted. Estimating fair value for share-based payment transactions requires determining the most appropriate valuation model, which is dependent on the terms and conditions of the grant. This estimate also requires determining the most appropriate inputs to the valuation model including the fair value of the underlying common shares, the expected life of the share option, volatility and dividend yield and making assumptions about them. The assumptions and models used for estimating fair value for share-based payment transactions are discussed in Note 9.</p>
CY2021Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
57102159
CY2022Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
110200000
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
72390
CY2021Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
57100000
CY2022Q3 us-gaap Debt Securities Available For Sale Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
58665
CY2022 us-gaap Gain Loss On Sale Of Investments
GainLossOnSaleOfInvestments
0
CY2021 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
10344000
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
4.46
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6803230
CY2022Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
109833757
CY2022Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
58666
CY2022Q3 us-gaap Debt Securities Available For Sale Accrued Interest After Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss
385938
CY2022Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
110161029
CY2021Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
57026103
CY2021Q3 us-gaap Debt Securities Available For Sale Accrued Interest After Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss
76056
CY2022Q3 us-gaap Prepaid Insurance
PrepaidInsurance
1611516
CY2021Q3 us-gaap Prepaid Insurance
PrepaidInsurance
1751052
CY2022Q3 epix Prepaid Preclinical And Clinical Expenses And Deposits
PrepaidPreclinicalAndClinicalExpensesAndDeposits
181835
CY2021Q3 epix Prepaid Preclinical And Clinical Expenses And Deposits
PrepaidPreclinicalAndClinicalExpensesAndDeposits
240513
CY2022Q3 us-gaap Prepaid Expense And Other Assets
PrepaidExpenseAndOtherAssets
22275
CY2021Q3 us-gaap Prepaid Expense And Other Assets
PrepaidExpenseAndOtherAssets
190317
CY2022Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1815626
CY2021Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
2181882
CY2022Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
954598
CY2021Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
1425871
CY2022Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
807484
CY2021Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2062441
CY2022Q3 us-gaap Accrued Vacation Current
AccruedVacationCurrent
414483
CY2021Q3 us-gaap Accrued Vacation Current
AccruedVacationCurrent
320632
CY2022Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
2176565
CY2021Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
3808944
CY2020Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
55162
CY2021 epix Operating Lease Right Of Use Asset Addition
OperatingLeaseRightOfUseAssetAddition
362588
CY2021 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
109464
CY2021Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
308286
CY2022 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
121787
CY2022Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
186499
CY2020Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
59094
CY2021 epix Operating Lease Liabilities Addition
OperatingLeaseLiabilitiesAddition
362588
CY2021 epix Operating Lease Liabilities Accretion Expenses
OperatingLeaseLiabilitiesAccretionExpenses
9570
CY2021 us-gaap Operating Lease Payments
OperatingLeasePayments
100282
CY2021Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
330970
CY2022 epix Operating Lease Liabilities Accretion Expenses
OperatingLeaseLiabilitiesAccretionExpenses
13305
CY2022 us-gaap Operating Lease Payments
OperatingLeasePayments
134023
CY2020Q3 us-gaap Derivative Liabilities
DerivativeLiabilities
127376
CY2021 us-gaap Increase Decrease In Derivative Liabilities
IncreaseDecreaseInDerivativeLiabilities
107024
CY2021Q3 us-gaap Derivative Liabilities
DerivativeLiabilities
20352
CY2022 us-gaap Increase Decrease In Derivative Liabilities
IncreaseDecreaseInDerivativeLiabilities
20352
CY2022Q3 us-gaap Derivative Liabilities
DerivativeLiabilities
0
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5309584
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.42
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1889646
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
9.87
CY2021 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
323610
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.20
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1347500
CY2022 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
4.55
CY2022 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
72910
CY2022 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
4.41
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
175759
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
3.60
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
7902061
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.13
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
4628477
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
4.59
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
7902061
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y6M29D
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1347500
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1889646
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.20
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
8.04
CY2020Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
9272977
CY2020Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
1.73
epix Class Of Warrant Or Right Exercised
ClassOfWarrantOrRightExercised
6038227
epix Class Of Warrant Or Right Weighted Average Exercise Price Warrants Exercised
ClassOfWarrantOrRightWeightedAverageExercisePriceWarrantsExercised
-0.06
CY2022Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
3234750
CY2022Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
4.84
CY2022Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
3234750
CY2022 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.270
CY2021 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.270
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-35215072
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-36839810
CY2022 epix Income Tax Reconciliation Expected Income Tax Recovery
IncomeTaxReconciliationExpectedIncomeTaxRecovery
9509000
CY2021 epix Income Tax Reconciliation Expected Income Tax Recovery
IncomeTaxReconciliationExpectedIncomeTaxRecovery
9947000
CY2022 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
963000
CY2021 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
1575000
CY2022 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
-25000
CY2021 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
-49000
CY2021 epix Income Tax Reconciliation Financing Costs
IncomeTaxReconciliationFinancingCosts
-2492000
CY2022 us-gaap Income Tax Reconciliation Foreign Income Tax Rate Differential
IncomeTaxReconciliationForeignIncomeTaxRateDifferential
1288000
CY2021 us-gaap Income Tax Reconciliation Foreign Income Tax Rate Differential
IncomeTaxReconciliationForeignIncomeTaxRateDifferential
1260000
CY2022 us-gaap Income Tax Reconciliation Prior Year Income Taxes
IncomeTaxReconciliationPriorYearIncomeTaxes
165000
CY2021 us-gaap Income Tax Reconciliation Prior Year Income Taxes
IncomeTaxReconciliationPriorYearIncomeTaxes
-725000
CY2022 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
7007000
CY2022Q3 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
37710000
CY2021Q3 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
29749000
CY2022Q3 epix Deferred Tax Assets Equipment And Intangible Assets
DeferredTaxAssetsEquipmentAndIntangibleAssets
77000
CY2021Q3 epix Deferred Tax Assets Equipment And Intangible Assets
DeferredTaxAssetsEquipmentAndIntangibleAssets
77000
CY2022Q3 us-gaap Deferred Tax Assets Investments
DeferredTaxAssetsInvestments
29000
CY2021Q3 us-gaap Deferred Tax Assets Investments
DeferredTaxAssetsInvestments
29000
CY2022Q3 epix Deferred Tax Assets Financing Costs
DeferredTaxAssetsFinancingCosts
2026000
CY2021Q3 epix Deferred Tax Assets Financing Costs
DeferredTaxAssetsFinancingCosts
3025000
CY2022Q3 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
210000
CY2021Q3 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
210000
CY2022Q3 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
125000
CY2021Q3 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
79000
CY2022Q3 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
40177000
CY2021Q3 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
33169000
CY2022Q3 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
40177000
CY2021Q3 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
33169000
CY2022Q3 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0
CY2021Q3 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0
CY2021 epix Stock Issued During Period Value Pre Funded Warrants Exercised
StockIssuedDuringPeriodValuePreFundedWarrantsExercised
81303
CY2021 epix Pre Funded Warrants Exercised
PreFundedWarrantsExercised
94723
CY2022 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2022Q3 epix Cash Canada Deposit Insurance Corporation Insured Amount
CashCanadaDepositInsuranceCorporationInsuredAmount
100000
CY2022Q3 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
250000
CY2022Q3 epix Working Capital
WorkingCapital
166765422

Files In Submission

Name View Source Status
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
0001558370-22-018570-index-headers.html Edgar Link pending
0001558370-22-018570-index.html Edgar Link pending
0001558370-22-018570.txt Edgar Link pending
0001558370-22-018570-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tmb-20220930.xsd Edgar Link pending
tmb-20220930x10k.htm Edgar Link pending
tmb-20220930x10k001.jpg Edgar Link pending
tmb-20220930x10k002.jpg Edgar Link pending
tmb-20220930xex21d1.htm Edgar Link pending
tmb-20220930xex23d1.htm Edgar Link pending
tmb-20220930xex23d1001.jpg Edgar Link pending
tmb-20220930xex23d1002.jpg Edgar Link pending
tmb-20220930xex31d1.htm Edgar Link pending
tmb-20220930xex31d2.htm Edgar Link pending
tmb-20220930xex32d1.htm Edgar Link pending
tmb-20220930xex4d2.htm Edgar Link pending
tmb-20220930_def.xml Edgar Link unprocessable
tmb-20220930_pre.xml Edgar Link unprocessable
tmb-20220930_cal.xml Edgar Link unprocessable
tmb-20220930_lab.xml Edgar Link unprocessable
tmb-20220930x10k_htm.xml Edgar Link completed